[Splenectomy in programmed therapy of aplastic anemia]

Area of Science:

• Hematology
• Surgical Oncology

Background:

• Aplastic anemia (AA) is a rare but serious bone marrow failure disorder.
• Current treatment paradigms for AA involve immunosuppressive therapy (IST).

Purpose of the Study:

• To evaluate the efficacy of splenectomy (SE) as a standalone treatment and as part of programmed therapy for aplastic anemia (AA).

Main Methods:

• A retrospective analysis of 74 AA patients treated with SE monotherapy (1986-1996).
• An analysis of SE within IST programs (including antilymphocytic globulin (ALG) and cyclosporin A (CsA)) for 69 AA patients (1991-2002).

Main Results:

• SE monotherapy improved AA in 73.3% of non-severe AA (NAA) patients and 18.2% of severe AA (SAA) patients, with 80% 3- and 5-year survival in NAA.
• Combined therapy (ALG, CsA, SE) showed an 85.5% response rate (81% in SAA).
• SE improved outcomes in SAA patients during second-stage treatment, with 60% long-term survival.

Conclusions:

• Splenectomy (SE) is an alternative to antilymphocytic globulin (ALG) in non-severe aplastic anemia (NAA) when combined with cyclosporin A (CsA).
• In severe aplastic anemia (SAA), SE can be used in the first stage for ALG intolerance or absence, and in the second stage to overcome treatment resistance.